Role of invariant NK T lymphocytes in immune responses to CPG oligodeoxynucleotides

Journal of Immunology

Volumn 182, Issue 4, 2009, Pages 1846-1853

  Paget, Christophe ^b   Bialecki, Emilie ^b   Fontaine, Josette ^b   Vendeville, Catherine ^b   Mallevaey, Thierry ^a   Faveeuw, Christelle ^b   Trottein, François ^b  

^a NATIONAL JEWISH MEDICAL AND RESEARCH CENTER   (United States)

^b NONE

Author keywords

[No Author keywords available]

Indexed keywords

CD1D ANTIGEN; CPG OLIGODEOXYNUCLEOTIDE; GAMMA INTERFERON; INTERLEUKIN 12; INTERLEUKIN 13; INTERLEUKIN 4; INTERLEUKIN 5; KEYHOLE LIMPET HEMOCYANIN; ODN 1826; UNCLASSIFIED DRUG; CPG ODN 1826; DNA; IMMUNOLOGICAL ADJUVANT;

ANIMAL CELL; ANIMAL EXPERIMENT; ANIMAL MODEL; ANTINEOPLASTIC ACTIVITY; ARTICLE; CELL ACTIVATION; CONTROLLED STUDY; CYTOKINE PRODUCTION; DENDRITIC CELL; FEMALE; IMMUNE RESPONSE; IMMUNIZATION; IN VITRO STUDY; IN VIVO STUDY; INNATE IMMUNITY; INTERFERON PRODUCTION; LIVER CELL; LUNG METASTASIS; MELANOMA; MOUSE; NATURAL KILLER CELL; NATURAL KILLER T CELL; NONHUMAN; PRIORITY JOURNAL; REGULATORY MECHANISM; SPLEEN CELL; TH1 CELL; TRANSACTIVATION; WILD TYPE; ANIMAL; BIOSYNTHESIS; EXPERIMENTAL MELANOMA; IMMUNOLOGY; LYMPHOCYTE ACTIVATION;

ADJUVANTS, IMMUNOLOGIC; ANIMALS; DNA; FEMALE; INTERFERON-GAMMA; LYMPHOCYTE ACTIVATION; MELANOMA, EXPERIMENTAL; MICE; NATURAL KILLER T-CELLS; TH1 CELLS;

EID: 61449222830     PISSN: 00221767     EISSN: 15506606     Source Type: Journal    
DOI: 10.4049/jimmunol.0802492     Document Type: Article

References (34)

1. Klinman, D. M. 2004. Immunotherapeutic uses of CpG oligodeoxynucleotides. Nat. Rev. Immunol. 4: 249-258.
2. Krieg, A. M. 2002. CpG motifs in bacterial DNA and their immune effects. Annu. Rev. Immunol. 20: 709-760.
3. Krieg, A. M. 2006. Therapeutic potential of Toll-like receptor 9 activation. Nat. Rev. Drug Discov. 5: 471-484.
4. Krieg, A. M. 2007. Development of TLR9 agonists for cancer therapy. J. Clin. Invest. 117: 1184-1194.
5. Hemmi, H., T. Kaisho, K. Takeda, and S. Akira. 2003. The roles of Toll-like receptor 9, MyD88, and DNA-dependent protein kinase catalytic subunit in the effects of two distinct CpG DNAs on dendritic cell subsets. J. Immunol. 170: 3059-3064.
6. Spies, B., H. Hochrein, M. Vabulas, K. Huster, D. H. Busch, F. Schmitz, A. Heit, and H. Wagner. 2003. Vaccination with plasmid DNA activates dendritic cells via Toll-like receptor 9 (TLR9) but functions in TLR9-deficient mice. J. Immunol. 171: 5908-5912.
7. Marschner, A., S. Rothenfusser, V. Hornung, D. Prell, A. Krug, M. Kerkmann, D. Wellisch, H. Poeck, A. Greinacher, T. Giese, et al. 2005. CpG ODN enhance antigen-specific NKT cell activation via plasmacytoid dendritic cells. Eur. J. Immunol. 35: 2347-2357.
8. Montoya, C. J., H. B. Jie, L. Al-Harthi, C. Mulder, P. J. Patino, M. T. Rugeles, A. M. Krieg, A. L. Landay, and S. B. Wilson. 2006. Activation of plasmacytoid dendritic cells with TLR9 agonists initiates invariant NKT cell-mediated crosstalk with myeloid dendritic cells. J. Immunol. 177: 1028-1039.
9. Paget, C., T. Mallevaey, A. O. Speak, D. Torres, J. Fontaine, K. C. Sheehan, M. Capron, B. Ryffel, C. Faveeuw, M. Leite de Moraes, et al. 2007. Activation of invariant NKT cells by toll-like receptor 9-stimulated dendritic cells requires type I interferon and charged glycosphingolipids. Immunity 27: 597-609.
10. Bendelac, A., P. B. Savage, and L. Teyton. 2006. The biology of NKT cells. Annu. Rev. Immunol. 25: 297-336.
11. Godfrey, D. I., and M. Kronenberg. 2004. Going both ways: immune regulation via CD1d-dependent NKT cells. J. Clin. Invest. 114: 1379-1388.
12. Van Kaer, L., and S. Joyce. 2005. Innate immunity: NKT cells in the spotlight. Curr. Biol. 15: R429-R431.
13. Kawano, T., J. Cui, Y. Koezuka, I. Toura, Y. Kaneko, K. Motoki, H. Ueno, R. Nakagawa, H. Sato, E. Kondo, et al. 1997. CD1d-restricted and TCR-mediated activation of vα14 NKT cells by glycosylceramides. Science 278: 1626-1629.
14. Mendiratta, S. K., W. D. Martin, S. Hong, A. Boesteanu, S. Joyce, and L. Van Kaer. 1997. CD1d1 mutant mice are deficient in natural T cells that promptly produce IL-4. Immunity 6: 469-477.
15. Adachi, O., T. Kawai, K. Takeda, M. Matsumoto, H. Tsutsui, M. Sakagami, K. Nakanishi, and S. Akira. 1998. Targeted disruption of the MyD88 gene results in loss of IL-1- and IL-18-mediated function. Immunity 9: 143-150.
16. Smyth, M. J., M. E. Wallace, S. L. Nutt, H. Yagita, D. I. Godfrey, and Y. Hayakawa. 2005. Sequential activation of NKT cells and NK cells provides effective innate immunotherapy of cancer. J. Exp. Med. 201: 1973-1985.
17. Hafner, M., R. Zawatzky, C. Hirtreiter, W. A. Buurman, B. Echtenacher, T. Hehlgans, and D. N. Mannel. 2001. Antimetastatic effect of CpG DNA mediated by type I IFN. Cancer Res. 61: 5523-5528.
18. Suzuki, Y., D. Wakita, K. Chamoto, Y. Narita, T. Tsuji, T. Takeshima, H. Gyobu, Y. Kawarada, S. Kondo, S. Akira, et al. 2004. Liposome-encapsulated CpG oligodeoxynucleotides as a potent adjuvant for inducing type 1 innate immunity. Cancer Res. 64: 8754-8760.
19. Tupin, E., Y. Kinjo, and M. Kronenberg. 2007. The unique role of natural killer T cells in the response to microorganisms. Nat. Rev. Microbiol. 5: 405-417.
20. Leite-De-Moraes, M. C., A. Hameg, A. Arnould, F. Machavoine, Y. Koezuka, E. Schneider, A. Herbelin, and M. Dy. 1999. A distinct IL-18-induced pathway to fully activate NK T lymphocytes independently from TCR engagement. J. Immunol. 163: 5871-5876.
21. Brigl, M., L. Bry, S. C. Kent, J. E. Gumperz, and M. B. Brenner. 2003. Mechanism of CD1d-restricted natural killer T cell activation during microbial infection. Nat. Immunol. 4: 1230-1237.
22. Nagarajan, N. A., and M. Kronenberg. 2007. Invariant NKT cells amplify the innate immune response to lipopolysaccharide. J. Immunol. 178: 2706-2713.
23. Wesley, J. D., M. S. Tessmer, D. Chaukos, and L. Brossay. 2008. NK cell-like behavior of Vα14i NK T cells during MCMV infection. PLoS Pathog. 4: e1000106.
24. Hou, B., B. Reizis, and A. L. Defranco. 2008. Toll-like receptors activate innate and adaptive immunity by using dendritic cell-intrinsic and -extrinsic mechanisms. Immunity 29: 272-282.
25. Wilson, M. T., C. Johansson, D. Olivares-Villagomez, A. K. Singh, A. K. Stanic, C. R. Wang, S. Joyce, M. J. Wick, and L. Van Kaer. 2003. The response of natural killer T cells to glycolipid antigens is characterized by surface receptor down-modulation and expansion. Proc. Natl. Acad. Sci. USA 100: 10913-10918.
26. Link, B. K., Z. K. Ballas, D. Weisdorf, J. E. Wooldridge, A. D. Bossler, M. Shannon, W. L. Rasmussen, A. M. Krieg, and G. J. Weiner. 2006. Oligodeoxynucleotide CpG 7909 delivered as intravenous infusion demonstrates immunologic modulation in patients with previously treated non-Hodgkin lymphoma. J. Immunother. 29: 558-568.
27. Tsujimoto, H., S. Ono, A. Matsumoto, T. Kawabata, M. Kinoshita, T. Majima, S. Hiraki, S. Seki, L. L. Moldawer, and H. Mochizuki. 2006. A critical role of CpG motifs in a murine peritonitis model by their binding to highly expressed Toll-like receptor-9 on liver NKT cells. J. Hepatol. 45: 836-843.
28. Mattner, J., K. L. Debord, N. Ismail, R. D. Goff, C. Cantu, 3rd, D. Zhou, P. Saint-Mezard, V. Wang, Y. Gao, N. Yin, et al. 2005. Exogenous and endogenous glycolipid antigens activate NKT cells during microbial infections. Nature 434: 525-529.
29. Tyznik, A. J., E. Tupin, N. A. Nagarajan, M. J. Her, C. A. Benedict, and M. Kronenberg. 2008. Cutting edge: the mechanism of invariant NKT cell responses to viral danger signals. J. Immunol. 181: 4452-4456.
30. Krug, A., S. Rothenfusser, V. Hornung, B. Jahrsdorfer, S. Blackwell, Z. K. Ballas, S. Endres, A. M. Krieg, and G. Hartmann. 2001. Identification of CpG oligonucleotide sequences with high induction of IFN-α/β in plasmacytoid dendritic cells. Eur. J. Immunol. 31: 2154-2163.
31. Zanoni, I., M. Foti, P. Ricciardi-Castagnoli, and F. Granucci. 2005. TLR-dependent activation stimuli associated with Th1 responses confer NK cell stimulatory capacity to mouse dendritic cells. J. Immunol. 175: 286-292.
32. Marshall, J. D., D. S. Heeke, C. Abbate, P. Yee, and G. Van Nest. 2006. Induction of interferon-γ from natural killer cells by immunostimulatory CpG DNA is mediated through plasmacytoid-dendritic-cell-produced interferon-α and tumour necrosis factor-α. Immunology 117: 38-46.
33. Sfondrini, L., D. Besusso, M. T. Zoia, M. Rodolfo, A. M. Invernizzi, M. Taniguchi, T. Nakayama, M. P. Colombo, S. Menard, and A. Balsari. 2002. Absence of the CD1 molecule up-regulates antitumor activity induced by CpG oligodeoxynucleotides in mice. J. Immunol. 169: 151-158.
34. + T cell-mediated eradication of established tumors by peritumoral injection of CpG-containing oligodeoxynucleotides. J. Immunol. 167: 5247-5253.